Herbal Medicine

Webinar: CBD for Anxiety & Depression--Case Studies & Clinical Pearls

By Erik Goldman

CV Sci Shunney Webinar

 

VIEW WEBINAR

Information about CBD (cannibidiol) and the endocannabinoid system is everywhere these days. So are claims about the health benefits of CBD. As compelling as these topics may be, the information presented is rarely clinically applicable.

What practitioners want--and need--is more information and guidance on how to use CBD safely and effectively in clinical practice.

In this free need-to-know primer, Aimée Shunney, ND, will share 3 case studies from her practice focusing on the use of CBD to increase stress resilience, reduce anxiety, and manage depression.

From these cases, she'll draw out key clinical pearls for patient care strategies, avoidance of drug interactions, selection of products, and more.

 

VIEW WEBINAR

Learning Objectives:

  • Learn about three patients’ successful experiences using CBD for depression and anxiety
  • Explore dosing strategies and practicalities of dosing titration
  • Review known issues with cannabinoid-drug interactions
  • Discuss challenges with extreme variation in products, including full spectrum products vs isolates
  • Learn various ways to balance the endocannabinoid system
  • Gain a clear understanding of how to choose superior products

Sponsored By

CV Logo Square

Dr. Aimee Shunney HeadshotAimée Gould Shunney, ND, is a naturopathic physician in private practice since 2001, currently at Santa Cruz Integrative Medicine in Santa Cruz, CA. She combines western medical science with evidence-based natural therapies including diet, exercise, lifestyle coaching, nutritional supplements, herbal medicine, and bio-identical hormones. She specializes in women’s health and bio- identical hormone balancing as well as menopause, menstrual issues, sexual dysfunction, thyroid optimization, stress management, and digestive health.

Quality Assurance for Hemp CBD: Key Questions to Ask

By Erik Goldman, Editor in Chief

Quality assurance is a challenge for all herbal companies. For those making hemp extracts, the challenges are compounded by a confusing regulatory landscape, the inherent complexity of the plant, the surging consumer demand for CBD, and the entrance of dozens of upstart brands with no prior herbal experience and little understanding of basic QA methods.

Regulatory Confusion Reigns As FDA Grapples With CBD

By Erik Goldman, Editor in Chief

On July 30, former FDA Commissioner, Scott Gottlieb, published an op/ed in the Washington Post saying that the agency needs to get a grip on the "out of hand" CBD craze. But it's a tall order. In many ways, CBD epitomizes all the conflicting motives and scientific ambiguities with which the FDA must constantly contend.

A Guide to the Endocannabinoid System

By Jamie Corroon, ND, MPH & Jake Felice, ND

Interest in the medical use of phytocannabinoids from Cannabis Sativa L. (Cannabis) has reached an all-time high. These exogenous, plant-derived ligands interact with endogenously produced proteins, receptors, enzymes and endogenous ligands, in one of the most evolutionarily preserved biological systems known to the life sciences: the endogenous cannabinoid signaling system, better known as the endocannabinoid system (ECS).

Hemp & CBD: Evidence, Evangelism & Extreme Exuberance

By Erik Goldman, Editor

If you are confused about the therapeutic value of hemp oil, cannabidiol (CBD), and other cannabis-related substances, and you’re scratching your head trying to figure out what’s legal and what’s not, that’s good: It means you’re paying attention.  Yes, there is some evidence, but there's also a lot of evangelism. Clinicians face the challenge of separating the scientific realities from the hype. 

Cannabis: State of the Science

By Erik Goldman, Editor

Is there any solid science to support the use of phytocannabinoids in clinical practice? The answer is yes….and no.

It depends on how you define “cannabis” and “cannabinoids;” whether you’re talking about inhaled (ie, smoked or vaped), ingested, or sublingual delivery; and of course, which diseases you’re considering.

Cannabis & Hemp: A Regulatory Update

By Erik Goldman, Editor

The year 2018 was a landmark in the history of hemp and cannabis in the US. It was the year the FDA approved the first natural cannabis-derived prescription drug, and Congress passed a Farm Bill that included provisions legalizing cultivation of, and interstate commerce in, low-THC hemp. But the laws and regulation around hemp and cannabis remain a confusing patchwork, and some states are taking regulatory actions that run counter to the new federal provisions.

Cannabis, Hemp, Marijuana: What's in a Name?

By Erik Goldman, Editor

Amid the current rage for all things cannabis, there is a lot of confusion about the terminology used to describe this plant and compounds extracted from it.

Part of that confusion arises from the Farm Bill of 2018, which changes some federal definitions. These changes have major implications for legal and regulatory policy.  Here’s a guide to common cannabis-related terms and their current definitions.